BioCentury | Feb 5, 2019
Distillery Therapeutics

Cancer

...has CX-4945, an oral protein kinase CSNK2 inhibitor, in Phase II testing for biliary cancer. Curtana Pharmaceuticals Inc....
BioCentury | Aug 17, 2017
Translation in Brief

Stopping the invasion

...after the standard of care to prevent the growth of the recurrent tumor." Gordon Alton, Curtana Pharmaceuticals...
...or CSNK2 inhibition in his preclinical models. Gordon Alton, VP of research and development at Curtana Pharmaceuticals Inc....
...et al. "Identification of a druggable pathway controlling glioblastoma invasiveness." Cell Reports (2017) Winnie Pong, Staff Writer CX-4945 Curtana Pharmaceuticals Inc. Netherlands...
BioCentury | Jul 12, 2017
Emerging Company Profile

Epigenetics: It’s personal

...In addition, there are at least 13 cancer stem cell companies with development programs and Curtana Pharmaceuticals Inc....
...Funds raised: Undisclosed Investors: Undisclosed CEO: Attila Hajdu Patents: None issued Companies and Institutions Mentioned Curtana Pharmaceuticals Inc....
...Bone morphogenetic protein 4 References Martz, L., “Stemming the tide.” BioCentury Innovations (2017) Michael Leviten, Senior Writer Curtana Pharmaceuticals Stelvio...
BioCentury | May 11, 2017
Tools & Techniques

Stemming the tide

...with Merck & Co. Inc. (NYSE:MRK) to study defactinib with MRK compounds Ph I/II ongoing Curtana Pharmaceuticals Inc....
BioCentury | May 19, 2014
Emerging Company Profile

Curtana: Curtains for CSCs

...complete some of its preclinical work and is seeking additional funding. Companies and Institutions Mentioned Curtana Pharmaceuticals Inc....
...Diego, Calif. University of California, San Diego, School of Medicine , San Diego, Calif. Sidebars Curtana Pharmaceuticals Inc....
BioCentury | Dec 9, 2013
Company News

Curtana Pharmaceuticals, University of California deal

...Curtana plans to submit an IND in about three years. Curtana declined to disclose details. Curtana Pharmaceuticals Inc....
Items per page:
1 - 6 of 6
BioCentury | Feb 5, 2019
Distillery Therapeutics

Cancer

...has CX-4945, an oral protein kinase CSNK2 inhibitor, in Phase II testing for biliary cancer. Curtana Pharmaceuticals Inc....
BioCentury | Aug 17, 2017
Translation in Brief

Stopping the invasion

...after the standard of care to prevent the growth of the recurrent tumor." Gordon Alton, Curtana Pharmaceuticals...
...or CSNK2 inhibition in his preclinical models. Gordon Alton, VP of research and development at Curtana Pharmaceuticals Inc....
...et al. "Identification of a druggable pathway controlling glioblastoma invasiveness." Cell Reports (2017) Winnie Pong, Staff Writer CX-4945 Curtana Pharmaceuticals Inc. Netherlands...
BioCentury | Jul 12, 2017
Emerging Company Profile

Epigenetics: It’s personal

...In addition, there are at least 13 cancer stem cell companies with development programs and Curtana Pharmaceuticals Inc....
...Funds raised: Undisclosed Investors: Undisclosed CEO: Attila Hajdu Patents: None issued Companies and Institutions Mentioned Curtana Pharmaceuticals Inc....
...Bone morphogenetic protein 4 References Martz, L., “Stemming the tide.” BioCentury Innovations (2017) Michael Leviten, Senior Writer Curtana Pharmaceuticals Stelvio...
BioCentury | May 11, 2017
Tools & Techniques

Stemming the tide

...with Merck & Co. Inc. (NYSE:MRK) to study defactinib with MRK compounds Ph I/II ongoing Curtana Pharmaceuticals Inc....
BioCentury | May 19, 2014
Emerging Company Profile

Curtana: Curtains for CSCs

...complete some of its preclinical work and is seeking additional funding. Companies and Institutions Mentioned Curtana Pharmaceuticals Inc....
...Diego, Calif. University of California, San Diego, School of Medicine , San Diego, Calif. Sidebars Curtana Pharmaceuticals Inc....
BioCentury | Dec 9, 2013
Company News

Curtana Pharmaceuticals, University of California deal

...Curtana plans to submit an IND in about three years. Curtana declined to disclose details. Curtana Pharmaceuticals Inc....
Items per page:
1 - 6 of 6